Connection

Igor Roninson to Protein Kinase Inhibitors

This is a "connection" page, showing publications Igor Roninson has written about Protein Kinase Inhibitors.
Connection Strength

1.061
  1. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition. Cells. 2019 11 09; 8(11).
    View in: PubMed
    Score: 0.554
  2. Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in?vitro and in?vivo. Proc Natl Acad Sci U S A. 2022 08 09; 119(32):e2201073119.
    View in: PubMed
    Score: 0.167
  3. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022 02 24; 65(4):3420-3433.
    View in: PubMed
    Score: 0.162
  4. The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs. Cells. 2021 01 12; 10(1).
    View in: PubMed
    Score: 0.150
  5. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget. 2017 Feb 21; 8(8):12558-12575.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.